NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington's disease mouse modelDaniele Moretti, Alberto Bresciani, Celia Dominquez et al.|Free Radical Biology and Medicine|2020Cited by 49
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)Alberto Bresciani, Larry C. Park, Antonino Missineo et al.|Archives of Biochemistry and Biophysics|2017Cited by 45
Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 InteractionJesus M. Ontoria, Steven J. Harper, Ilaria Biancofiore et al.|ACS Medicinal Chemistry Letters|2020Cited by 29
A21 Development of an Nrf2-KEAP1 protein-protein disruptor for proof of conceptAlberto Bresciani, Larry Park, Mauro Cerretani et al.|Journal of Neurology Neurosurgery & Psychiatry|2016Cited by 2